Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
INMB 
INmune Bio Inc (INMB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: INMB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.25
1 Year Target Price $5.25
| 2 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0.88% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 49.18M USD | Price to earnings Ratio - | 1Y Target Price 5.25 |
Price to earnings Ratio - | 1Y Target Price 5.25 | ||
Volume (30-day avg) 5 | Beta 1.05 | 52 Weeks Range 1.71 - 10.50 | Updated Date 10/17/2025 |
52 Weeks Range 1.71 - 10.50 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.49 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -79430% |
Management Effectiveness
Return on Assets (TTM) -55.08% | Return on Equity (TTM) -168.34% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 23969452 | Price to Sales(TTM) 983.65 |
Enterprise Value 23969452 | Price to Sales(TTM) 983.65 | ||
Enterprise Value to Revenue 479.39 | Enterprise Value to EBITDA -5.31 | Shares Outstanding 26585258 | Shares Floating 18722934 |
Shares Outstanding 26585258 | Shares Floating 18722934 | ||
Percent Insiders 24.61 | Percent Institutions 21.17 |
Upturn AI SWOT
INmune Bio Inc
Company Overview
History and Background
INmune Bio Inc. was founded in 2015. It's a clinical-stage biotechnology company focused on developing therapies that harness the power of the innate immune system to treat diseases.
Core Business Areas
- INKmune: INKmune is a Natural Killer (NK) cell therapeutic platform designed to enhance the cytotoxic activity of NK cells to eliminate tumor cells. It is being studied for the treatment of solid tumors.
- XPro1595: XPro1595 is a dominant-negative TNF inhibitor targeting soluble TNF (sTNF), a driver of inflammation. It is being studied for Alzheimer's disease and other neurodegenerative conditions.
Leadership and Structure
The leadership team includes Dr. Raymond Tesi (CEO), David Moss (CFO), and Christopher Barnum (Chief Business Officer). The company has a standard corporate structure with a board of directors and various functional departments.
Top Products and Market Share
Key Offerings
- INKmune: INKmune is a NK cell therapeutic platform for treating solid tumors. Market share data is currently unavailable due to its clinical-stage development. Competitors include companies developing other NK cell therapies, such as Fate Therapeutics (FATE) and NantKwest (NK). Revenue is zero as it is in clinical trials.
- XPro1595: XPro1595 is a dominant-negative TNF inhibitor for treating Alzheimer's disease and other neurodegenerative conditions. Market share data is unavailable due to its clinical-stage development. Competitors include companies developing Alzheimer's drugs, such as Biogen (BIIB) and Eli Lilly (LLY). Revenue is zero as it is in clinical trials.
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive and innovative, with significant investment in research and development. There is increasing demand for novel therapeutics to treat a wide range of diseases.
Positioning
INmune Bio Inc. is positioned as a clinical-stage company focused on developing innovative therapies targeting the innate immune system. Its competitive advantage lies in its unique approach to treating diseases by modulating the immune response.
Total Addressable Market (TAM)
The TAM for cancer and neurodegenerative disease treatments is substantial, estimated to be in the hundreds of billions of dollars. INmune Bio Inc. is targeting specific segments within these large markets with its novel therapies. Alzheimer's market alone is expected to reach $13.7 billion by 2030. INmune's XPro1595 is in Phase II clinical trials and if approved, would capture a portion of this growing market.
Upturn SWOT Analysis
Strengths
- Novel therapeutic platforms
- Strong intellectual property
- Experienced management team
- Targeting unmet medical needs
Weaknesses
- Clinical-stage company with no approved products
- High cash burn rate
- Dependence on clinical trial success
- Limited financial resources
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Accelerated regulatory pathways
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Economic downturn affecting investment in biotechnology
Competitors and Market Share
Key Competitors
- BIIB
- LLY
- FATE
- NK
Competitive Landscape
INmune Bio faces intense competition. Its advantage lies in its innovative approach, but it's disadvantaged by its size and limited resources compared to larger pharmaceutical companies. Competitors mentioned here reflect companies in the same disease targets; market share is a very rough estimate and would need specific disease state focus.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is marked by investments in clinical trials and expansion of its pipeline.
Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and commercialization strategies. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing clinical trials for INKmune and XPro1595 and exploring partnerships.
Summary
INmune Bio Inc. is a clinical-stage biotechnology company with promising therapeutic platforms targeting unmet medical needs. Its success hinges on positive clinical trial outcomes and securing strategic partnerships. The company faces significant financial risks and competition, but its innovative approach could lead to substantial growth if its therapies prove effective. Investors should closely monitor clinical trial results and financial performance.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided is based on publicly available information and may not be entirely accurate or complete. Investing in biotechnology companies involves significant risks, including the potential for loss of capital.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About INmune Bio Inc
Exchange NASDAQ | Headquaters Boca Raton, FL, United States | ||
IPO Launch date 2019-02-04 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.inmunebio.com |
Full time employees 13 | Website https://www.inmunebio.com | ||
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.